Page last updated: 2024-08-21

alpha-aminopyridine and Cerebral Infarction

alpha-aminopyridine has been researched along with Cerebral Infarction in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Cai, N; Chen, K; Li, M; Li, X; Qin, Y; Wang, H; Xu, B; Xu, J1
Hirata, K; Ishibashi, K; Ishii, K; Miura, Y; Toyohara, J1
Ishibashi, K; Ishii, K; Kameyama, M; Tago, T; Toyohara, J1

Other Studies

3 other study(ies) available for alpha-aminopyridine and Cerebral Infarction

ArticleYear
Roflumilast, a cyclic nucleotide phosphodiesterase 4 inhibitor, protects against cerebrovascular endothelial injury following cerebral ischemia/reperfusion by activating the Notch1/Hes1 pathway.
    European journal of pharmacology, 2022, Jul-05, Volume: 926

    Topics: Aminopyridines; Animals; Benzamides; Blood-Brain Barrier; Brain Ischemia; Cerebral Infarction; Cyclopropanes; Endothelial Cells; Humans; Ischemic Stroke; Nucleotides, Cyclic; Phosphodiesterase 4 Inhibitors; Rats; Receptor, Notch1; Reperfusion; Reperfusion Injury; Transcription Factor HES-1

2022
Relationship between the temporal course of astrogliosis and symptom improvement in cerebral infarction: report of a case monitored using
    BMC medical imaging, 2020, 07-14, Volume: 20, Issue:1

    Topics: Aged; Aminopyridines; Cerebral Infarction; Frontal Lobe; Gliosis; Humans; Male; Monoamine Oxidase; Positron-Emission Tomography; Quinolines; Somatosensory Cortex

2020
Potential Use of 18F-THK5351 PET to Identify Wallerian Degeneration of the Pyramidal Tract Caused by Cerebral Infarction.
    Clinical nuclear medicine, 2017, Volume: 42, Issue:12

    Topics: Adult; Aminopyridines; Cerebral Infarction; Humans; Male; Positron-Emission Tomography; Quinolines; Wallerian Degeneration

2017